申请人:Novo Nordisk A/S
公开号:US05075304A1
公开(公告)日:1991-12-24
New imidazoquinoxaline compounds having the general formula ##STR1## wherein R.sup.3 is ##STR2## or CO.sub.2 R' wherein R' is C.sub.3-7 -cycloalkyl; R.sup.5 is methyl, which is substituted with hydrogen, alkoxycarbonyl, heteroaryl, morpholino, C.sub.3-7 -cycloalkyl, C.sub.1-6 -alkenyl, arylacyl, alkylacyl, alkoxyalkyl, alkoxy, phthalimidophenyl, aralkyl or aryl, all of which are substituted with hydrogen, halogen, C.sub.1-6 -alkyl, amino, azido, or C.sub.1-6 -alkoxy; and R.sup.6 is H, C.sub.1-6 -alkyl, halogen, or CF.sub.3. The compounds are useful in psychopharmaceutical preparations as anticonvulsants, anxiolytics, hypnotics, and in improving the cognitive function of the brain of mammals.
具有以下一般式的新咪唑喹啉化合物:##STR1## 其中R.sup.3是##STR2## 或CO.sub.2 R',其中R'是C.sub.3-7-环烷基;R.sup.5是甲基,其被氢、烷氧基、杂环芳基、吗啉基、C.sub.3-7-环烷基、C.sub.1-6-烯基、芳基酰基、烷基酰基、烷氧基烷基、烷氧基、邻苯二酰亚胺苯基、芳基烷基或芳基取代,所有这些均被氢、卤素、C.sub.1-6-烷基、氨基、偶氮基或C.sub.1-6-烷氧基取代;R.sup.6是H、C.sub.1-6-烷基、卤素或CF.sub.3。这些化合物在精神药物制剂中作为抗癫痫药、抗焦虑药、催眠药以及改善哺乳动物大脑认知功能方面具有用途。